Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nyxoah S.A. (NYXH)
USD1.60
+0.02 (+1.27%)
BE NASDAQ Healthcare Medical - Specialties
Address
Rue Edouard Belin 12 1435
Mont-Saint-Guibert, WBR, BE
Mont-Saint-Guibert, WBR, BE
CEO
Olivier Taelman
Website
nyxoah.com
IPO
2021-04-28
CIK 1857190 ISIN BE0974358906
Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
News Sentiment (7d)
3 articles
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.60
+0.02 (+1.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
262.2K
Beta
0.89
Float Shares
20.74M
Free Float %
55.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.19% | -9.32% | -10.70% | -34.09% | -41.60% | -36.52% | -51.82% | -63.27% | -87.39% | -87.83% | -87.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.60
Low
5.00
+212.5%
Consensus
6.00
+275.0%
Median
6.00
+275.0%
High
7.00
+337.5%
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
5.00
+212.5%
|
| Last Quarter | 2 |
6.50
+306.3%
|
| Last Year | 4 |
8.25
+415.6%
|
| All Time | 11 |
16.09
+905.6%
|
Quality scores
Altman Z-Score
-6.47
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+121.6% ★ Q1'26: +501.1% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-30.9% Q1'26: +38.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-808.8% Q1'26: -349.6% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-872.1% Q1'26: -322.3% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%-202.3% Q1'26: -178.5% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+16.4% Q1'26: +15.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.51× Q1'26: -0.48× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
69.0K
est: 499.4K (-86.2%)
|
852.0K
est: 2.19M (-61.1%)
|
3.08M
est: 4.48M (-31.2%)
|
4.35M
est: 4.47M (-2.6%)
|
4.52M
est: 5.78M (-21.8%)
|
10.02M
est: 8.77M (+14.3%)
|
35.40M
33.35M – 37.24M
+303.7% YoY
|
72.91M
67.74M – 77.27M
+106.0% YoY
|
115.57M
100.72M – 124.85M
+58.5% YoY
|
182.48M
159.03M – 197.12M
+57.9% YoY
|
282.63M
246.31M – 305.32M
+54.9% YoY
|
| EBITDA |
-10.60M
est: -499.4K (-2,023.5%)
|
-22.59M
est: -2.19M (-930.7%)
|
-27.89M
est: -4.48M (-521.8%)
|
-42.08M
est: -4.47M (-842.4%)
|
-58.05M
est: -5.78M (-904.4%)
|
-82.90M
est: -8.77M (-845.4%)
|
-35.40M
-37.24M – -33.35M
-303.7% YoY
|
-72.91M
-77.27M – -67.74M
-106.0% YoY
|
-115.57M
-124.85M – -100.72M
-58.5% YoY
|
-182.48M
-197.12M – -159.03M
-57.9% YoY
|
-282.63M
-305.32M – -246.31M
-54.9% YoY
|
| EBIT |
-11.22M
est: -499.4K (-2,147.6%)
|
-24.25M
est: -2.19M (-1,006.5%)
|
-29.82M
est: -4.48M (-564.9%)
|
-44.44M
est: -4.47M (-895.3%)
|
-58.81M
est: -5.78M (-917.7%)
|
-87.39M
est: -8.77M (-896.5%)
|
-35.40M
-37.24M – -33.35M
-303.7% YoY
|
-72.91M
-77.27M – -67.74M
-106.0% YoY
|
-115.57M
-124.85M – -100.72M
-58.5% YoY
|
-182.48M
-197.12M – -159.03M
-57.9% YoY
|
-282.63M
-305.32M – -246.31M
-54.9% YoY
|
| Net Income |
-12.25M
est: -24.91M (+50.8%)
|
-27.62M
est: -34.09M (+19.0%)
|
-31.23M
est: -33.86M (+7.8%)
|
-43.21M
est: -51.29M (+15.7%)
|
-59.24M
est: -65.90M (+10.1%)
|
-90.09M
est: -76.67M (-17.5%)
|
-65.19M
-65.50M – -54.33M
+15.0% YoY
|
-60.86M
-69.57M – -27.02M
+6.6% YoY
|
-30.33M
-34.58M – -26.08M
+50.2% YoY
|
-4.65M
-5.14M – -3.88M
+84.7% YoY
|
10.47M
8.72M – 11.56M
+325.0% YoY
|
| SGA |
11.35M
est: 19.44M (-41.6%)
|
11.11M
est: 85.32M (-87.0%)
|
18.86M
est: 174.57M (-89.2%)
|
20.65M
est: 31.11M (-33.6%)
|
28.46M
est: 40.26M (-29.3%)
|
46.44M
est: 61.10M (-24.0%)
|
246.64M
232.32M – 259.43M
+303.7% YoY
|
507.99M
471.92M – 538.33M
+106.0% YoY
|
805.19M
701.72M – 869.82M
+58.5% YoY
|
1.27B
1.11B – 1.37B
+57.9% YoY
|
1.97B
1.72B – 2.13B
+54.9% YoY
|
| EPS |
-0.68
est: -0.76 (+10.6%)
|
-1.16
est: -1.04 (-11.4%)
|
-1.21
est: -1.04 (-15.9%)
|
-1.55
est: -1.39 (-11.6%)
|
-1.81
est: -1.74 (-3.8%)
|
-2.37
est: -2.12 (-11.6%)
|
-1.60
-1.72 – -1.43
+24.8% YoY
|
-1.18
-1.83 – -0.71
+25.8% YoY
|
-0.82
-0.91 – -0.68
+30.6% YoY
|
-0.12
-0.13 – -0.10
+85.1% YoY
|
0.27
0.23 – 0.30
+325.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-60.31M
OE per share TTM
-1.60
Owner's Yield
-45.14%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
170.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
720.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cochlear Investments Pty Ltd | 4.70M | 18.50% | — | 4.70M | — | 4.70M | CO | Australia | 2021-07-16 | ↗ |
| 2 | Cochlear Limited | 4.70M | 18.50% | — | 4.70M | — | 4.70M | CO | Australia | 2021-07-16 | ↗ |
| 3 | Edwin de Graaf | 3.15M | 12.24% | — | 3.15M | — | 3.15M | IN | — | 2022-02-10 | ↗ |
| 4 | Gilde Healthcare Holding B.V. | 3.15M | 12.24% | — | 3.15M | — | 3.15M | OO | — | 2022-02-10 | ↗ |
| 5 | Gilde Healthcare III Management B.V. | 3.15M | 12.24% | — | 3.15M | — | 3.15M | OO | — | 2022-02-10 | ↗ |
| 6 | Martemanshurk BV (100% owned by Pieter van der Meer) | 3.15M | 12.24% | — | 3.15M | — | 3.15M | OO | — | 2022-02-10 | ↗ |
| 7 | Robert Taub | 2.82M | 10.90% | 2.12M | 696.0K | 2.12M | 696.0K | IN | Belgium | 2022-02-11 | ↗ |
| 8 | TOGETHER Partnership | 2.50M | 9.70% | 2.50M | — | 2.50M | — | PN | Belgium | 2022-02-14 | ↗ |
| 9 | Cooperatieve Gilde Healthcare III Sub-Holding U.A. | 1.58M | 6.12% | — | 1.58M | — | 1.58M | OO | — | 2022-02-10 | ↗ |
| 10 | Sub-Holding | 1.58M | 6.12% | — | 1.58M | — | 1.58M | OO | — | 2022-02-10 | ↗ |
| 11 | ResMed Inc. | 1.50M | 5.38% | 1.50M | — | 1.50M | — | CO | Delaware | 2023-04-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-25 vs prev Q
New positions
3
Closed positions
28
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VESTAL POINT CAPITAL, LP | 1.11M -413.0 (0.0%) | 5.09M -1.9K (0.0%) | 2.96% -0.001 pp | 0.17% -0.057 pp | USD8.00 -42.5% | 5 qtrs — |
| 2 | HEIGHTS CAPITAL MANAGEMENT, INC | 777.2K +777.2K (+100.0%) | 3.58M +3.6M (+100.0%) | 2.08% +2.077 pp | 1.28% +1.282 pp | USD4.60 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 582.5K -160.9K (-21.6%) | 2.68M -739.9K (-21.6%) | 1.56% -0.430 pp | 0.00% +0.000 pp | USD9.54 -51.8% | 6 qtrs — |
| 4 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 493.2K +493.2K (+100.0%) | 2.02M +2.0M (+100.0%) | 1.32% +1.318 pp | 0.00% +0.002 pp | USD4.60 +0.0% | 1 qtrs NEW |
| 5 | ROSSMORE PRIVATE CAPITAL | 132.7K +— (+0.0%) | 636.8K +20.7K (+3.4%) | 0.35% +0.000 pp | 0.06% -0.010 pp | USD25.23 -81.8% | 18 qtrs — |
| 6 | FRANKLIN RESOURCES INC | 126.0K -74.7K (-37.2%) | 579.4K -343.6K (-37.2%) | 0.34% -0.200 pp | 0.00% 0.000 pp | USD10.45 -56.0% | 8 qtrs — |
| 7 | KOVACK ADVISORS, INC. | 62.8K -34.3K (-35.3%) | 288.8K -157.6K (-35.3%) | 0.17% -0.092 pp | 0.01% -0.029 pp | USD6.57 -30.0% | 6 qtrs — |
| 8 | SIO CAPITAL MANAGEMENT, LLC | 50.8K +— (+0.0%) | 233.9K +— (+0.0%) | 0.14% +0.000 pp | 0.04% -0.022 pp | USD9.25 -50.3% | 18 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 48.1K -48.4K (-50.2%) | 221.1K -222.4K (-50.2%) | 0.13% -0.129 pp | 0.00% 0.000 pp | USD7.03 -34.6% | 7 qtrs — |
| 10 | IKARIAN CAPITAL, LLC | 47.4K -3.3K (-6.5%) | 217.8K -15.0K (-6.5%) | 0.13% -0.009 pp | 0.02% -0.007 pp | USD7.48 -38.5% | 3 qtrs — |
| 11 | LPL FINANCIAL LLC | 35.9K -2.9K (-7.6%) | 165.0K -13.5K (-7.6%) | 0.10% -0.008 pp | 0.00% +0.000 pp | USD7.26 -36.6% | 5 qtrs — |
| 12 | CITADEL ADVISORS LLC | 35.3K +14.1K (+66.5%) | 162.5K +64.9K (+66.5%) | 0.09% +0.038 pp | 0.00% +0.000 pp | USD4.60 +0.0% | 2 qtrs — |
| 13 | DEUTSCHE BANK AG\ | 35.0K +10.0K (+40.0%) | 161.0K +46.0K (+40.0%) | 0.09% +0.027 pp | 0.00% +0.000 pp | USD4.60 +0.0% | 2 qtrs — |
| 14 | DEKABANK DEUTSCHE GIROZENTRALE | 26.2K +— (+0.0%) | 137.0K +21.0K (+18.1%) | 0.07% +0.000 pp | 0.00% +0.000 pp | USD9.20 -50.0% | 15 qtrs — |
| 15 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 23.3K -26.7K (-53.4%) | 107.2K -123.1K (-53.5%) | 0.06% -0.071 pp | 0.00% -0.001 pp | USD6.70 -31.3% | 8 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 19.7K -172.0 (-0.9%) | 90.6K -792.0 (-0.9%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD5.96 -22.8% | 12 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 18.6K +— (+0.0%) | 85.6K +— (+0.0%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD10.83 -57.5% | 8 qtrs — |
| 18 | WALLEYE CAPITAL LLC | 17.3K +— (+0.0%) | 79.6K +— (+0.0%) | 0.05% +0.000 pp | 0.00% 0.000 pp | USD6.99 -34.2% | 7 qtrs — |
| 19 | INVST, LLC | 16.3K +— (+0.0%) | 74.8K +— (+0.0%) | 0.04% +0.000 pp | 0.01% 0.000 pp | USD7.48 -38.5% | 3 qtrs — |
| 20 | RAYMOND JAMES FINANCIAL INC | 12.8K +— (+0.0%) | 58.7K +— (+0.0%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD6.72 -31.5% | 3 qtrs — |
| 21 | BOOTHBAY FUND MANAGEMENT, LLC | 11.5K -3.3K (-22.2%) | 52.8K -15.0K (-22.2%) | 0.03% -0.009 pp | 0.00% 0.000 pp | USD12.26 -62.5% | 8 qtrs — |
| 22 | ADVISOR GROUP HOLDINGS, INC. | 6.6K +— (+0.0%) | 31.7K -9.4K (-23.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD5.77 -20.3% | 4 qtrs — |
| 23 | UBS GROUP AG | 6.7K +1.4K (+25.1%) | 31.0K +6.2K (+25.1%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD4.84 -5.0% | 4 qtrs — |
| 24 | BARCLAYS PLC | 3.1K +3.1K (+100.0%) | 14.3K +14.3K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD4.60 +0.0% | 4 qtrs — |
| 25 | GHP INVESTMENT ADVISORS, INC. | 2.6K +— (+0.0%) | 11.9K +— (+0.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD7.48 -38.5% | 3 qtrs — |
| 26 | VERSANT CAPITAL MANAGEMENT, INC | 2.3K +2.3K (+100.0%) | 10.7K +10.7K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD4.60 +0.0% | 1 qtrs NEW |
| 27 | MORGAN STANLEY | 1.5K -1.0K (-40.4%) | 6.8K -4.6K (-40.4%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD7.57 -39.2% | 7 qtrs — |
| 28 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 1.0K +— (+0.0%) | 4.6K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.60 +0.0% | 2 qtrs — |
| 29 | ADVISORNET FINANCIAL, INC | 1.0K +— (+0.0%) | 4.6K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.60 +0.0% | 2 qtrs — |
| 30 | FOURTH DIMENSION WEALTH, LLC | 790.00 +— (+0.0%) | 3.6K +— (+0.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD6.02 -23.6% | 3 qtrs — |
| 31 | LARSON FINANCIAL GROUP LLC | 744.00 +— (+0.0%) | 3.4K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.48 -38.5% | 3 qtrs — |
| 32 | CHEVIOT VALUE MANAGEMENT, LLC | 200.00 +— (+0.0%) | 980.00 -34.0 (-3.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.98 -34.1% | 4 qtrs — |
| 33 | SBI SECURITIES CO., LTD. | 3.00 +— (+0.0%) | 14.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 -42.5% | 5 qtrs — |
| 34 | FMR LLC | — -48.7K (-100.0%) | — -224.0K (-100.0%) | 0.00% -0.130 pp | 0.00% +0.000 pp | USD— | 12 qtrs SOLD |
| 35 | SHAY CAPITAL LLC | — -34.0K (-100.0%) | — -156.4K (-100.0%) | 0.00% -0.091 pp | 0.00% -0.014 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-5.4K
Shares Outstanding
37.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bruno Onkelinx | Chief Technical Officer | 2M | male |
| Olivier Taelman | Chief Executive Officer & Executive Director | 1M | male |
| Loic Moreau | President of International | 552.4K | male |
| Robert Taub | Co-Founder & Chairman | 139.7K | male |
| Maggie McGowan | Chief HR Officer | — | female |
| Maurits S. Boon | Chief Medical Officer | — | — |
| Pearson Dennis | Investor Relations Associate | — | — |
| Remi Renard | Chief of Staff | — | male |
| An Moonen | General Counsel | — | female |
| Scott Holstine | Chief Commercial Officer | — | male |
| Geeta Kaveti | Chief Compliance Officer | — | female |
| Jeyakumar Subbaroyan | Chief Science Officer | — | male |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NYXH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
